Our Services
Medical Information
Helpful Resources
Published on: 9/22/2026
Common side effects of the Wegovy pill (oral semaglutide) include nausea, vomiting, diarrhea, constipation, stomach pain, heartburn, burping, fatigue, and headache, which most often begin in the first weeks of treatment or after a dose increase and typically ease within a few days to several weeks as the body adjusts. Timing varies by person, dose, and how quickly the dose is escalated, and rare but serious reactions such as pancreatitis, gallbladder problems, dehydration from persistent vomiting, or vision changes require prompt medical attention, so there are several important factors to consider below. Because "normal" adjustment symptoms and warning signs can feel similar, checking your specific symptoms is the fastest way to know whether waiting it out, adjusting your dose with your prescriber, or seeking urgent care is the right next step. A free, instant, online symptom check lets you enter what you are feeling in minutes and receive tailored insight on possible causes and the level of care to consider. Taking a few minutes now can spare you weeks of uncertainty and help you arrive at your next appointment with clear, specific information.
Last reviewed for medical accuracy: 09/22/2026
Wegovy (semaglutide) is a prescription medication approved by the FDA for weight management. Although it’s delivered as a once-weekly injection rather than a traditional pill, many people search for “wegovy pill side effects” when researching semaglutide. This guide covers the most common side effects, how long they typically last, and practical tips for managing them. Always refer to the prescribing information and speak with your healthcare provider for personalized advice.
Semaglutide works by mimicking a hormone called GLP-1, which helps regulate appetite, slow down stomach emptying, and improve blood sugar control. These effects on your digestive system and brain can lead to side effects as your body adjusts.
Clinical trials and post-marketing reports list the following as the most frequent side effects:
Most side effects follow a predictable pattern:
Here are practical strategies to ease discomfort without stopping Wegovy:
While most reactions are mild to moderate, some warrant immediate medical attention:
For any life-threatening or severe symptoms, call emergency services or go to the nearest ER. Otherwise, contact your healthcare provider promptly.
Keeping a side-effect diary can help you and your doctor spot patterns and make adjustments:
If you’re unsure about a symptom, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you decide whether to monitor your symptoms at home or seek medical advice.
Open communication with your healthcare team is key:
As your body adjusts, many side effects will fade. However:
Wegovy has been shown in clinical studies to help with significant, sustained weight loss and improvement in metabolic health. Mild to moderate side effects are common but usually transient. With proper management and open dialogue with your doctor, many people successfully continue treatment with minimal disruption to daily life.
Remember: This information is based on credible resources, including the FDA prescribing information and clinical trial data. It’s not a substitute for professional medical advice. If you experience serious side effects or have any concerns, please speak to your doctor right away.
(References)
* Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T, SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15. PMID: 27633186.
* Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.
* Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I, STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 13;397(10278):971-984. doi: 10.1016/S0140-6736(21)00213-0. Epub 2021 Mar 2. PMID: 33667417.
* Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D, STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224. PMID: 33755728; PMCID: PMC7988425.
* Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Wharton S, STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022 Oct;28(10):2083-2091. doi: 10.1038/s41591-022-02026-4. Epub 2022 Oct 10. PMID: 36216945; PMCID: PMC9556320.
* Tan HC, Dampil OA, Marquez MM. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022;37(2):65-72. doi: 10.15605/jafes.037.02.14. Epub 2022 Aug 23. PMID: 36578889; PMCID: PMC9758543.
* Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH, SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. PMID: 37952131.
* Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R, FLOW Trial Committees and Investigators. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24. PMID: 38785209.
* Bliddal H, Bays H, Czernichow S, Uddén Hemmingsson J, Hjelmesæth J, Hoffmann Morville T, Koroleva A, Skov Neergaard J, Vélez Sánchez P, Wharton S, Wizert A, Kristensen LE, STEP 9 Study Group. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med. 2024 Oct 31;391(17):1573-1583. doi: 10.1056/NEJMoa2403664. PMID: 39476339.
* Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8. PMID: 40196933; PMCID: PMC12000858.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.